RxDoctor Payments Data

Charlie le, MD

Family Medicine · Metairie, LANPI 1811152465

Payments from drug & device makers

$10,009in general payments, 2019–2025

Across 649 payments — averaging $15.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$2K
  • AstraZeneca$1K
  • Pfizer$717
  • Lilly USA, LLC$614
  • Novo Nordisk$537
  • plus $4K from 46 others

What the payments were for

  • Food & beverage$9,997100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,009 in reported general payments places this provider in the 90th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$46,074
Medicare patients
75
Services billed
403

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide61$67,451
EliquisApixaban50$51,460
Trelegy ElliptaFluticasone/Umeclidin/Vilanter49$39,407
JanuviaSitagliptin Phosphate28$32,421
MounjaroTirzepatide20$22,924
LinzessLinaclotide33$18,727
JardianceEmpagliflozin22$17,599
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl59$11,287
TradjentaLinagliptin15$7,466
Breztri AerosphereBudesonide/Glycopyr/Formoterol11$6,999
ZubsolvBuprenorphine Hcl/Naloxone Hcl11$5,823
PaxlovidNirmatrelvir/Ritonavir14$2,797
Albuterol Sulfate HfaAlbuterol Sulfate70$2,411
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,900
Omega-3 Acid Ethyl Esters13$1,453

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$537$67,45161 claims
PfizerEliquis, Paxlovid$717$54,25764 claims
GSKTrelegy Ellipta$1,580$39,40749 claims
MerckJanuvia$180$32,42128 claims
Boehringer IngelheimJardiance, Tradjenta$489$25,06637 claims
Lilly USA, LLCMounjaro$614$22,92420 claims
AbbVieLinzess$1,934$18,72733 claims
Hikma Pharmaceuticals USABuprenorphine-Naloxone$32$11,28759 claims
AstraZenecaBreztri Aerosphere$1,027$6,99911 claims
Orexo US, Inc.Zubsolv$87$5,82311 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →